Literature DB >> 21550768

Revision for recurrent instability: what are the predictors of failure?

Aaron H Carter1, Eoin C Sheehan, S M Javad Mortazavi, James J Purtill, Peter F Sharkey, Javad Parvizi.   

Abstract

Dislocation is a common complication following total hip arthroplasty (THA). In this study, we evaluated treatment strategies in patients undergoing revision THA for instability. A total of 156 hips in 154 patients underwent revision THA for instability between 2000 and 2007 at our institution. Demographic data and surgical treatment used were analyzed to determine risk factors for failure. Revision treatments included acetabular components in 100 hips, liner exchange in 56 hips, and femoral and acetabular components in 13 hips. Thirty-three (21.2%) had further dislocation. Isolated liner revision (P = .004), previous revision arthroplasty (P < .05), and the use of a 28-mm femoral head were associated with higher failure rates. A total of 20.3% (12/59) of constrained liners failed. Isolated liner exchange, history of revision, and use of a 28-mm head were associated with failure in revision THA for instability.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21550768     DOI: 10.1016/j.arth.2011.03.021

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  32 in total

1.  Unstable hip arthroplasties. A prospective cohort study on seventy dislocating hips followed up for four years.

Authors:  Olle Wallner; André Stark; Olle Muren; Thomas Eisler; Olof Sköldenberg
Journal:  Int Orthop       Date:  2014-11-13       Impact factor: 3.075

2.  Dual mobility cups for preventing early hip arthroplasty dislocation in patients at risk: experience in a county hospital.

Authors:  Sebastian S Mukka; Sarwar S Mahmood; Göran O Sjödén; Arkan S Sayed-Noor
Journal:  Orthop Rev (Pavia)       Date:  2013-06-11

Review 3.  Total hip arthroplasty instability treatment without dual mobility cups: brief overview and experience of other options.

Authors:  Luigi Zagra; Eleonora Caboni
Journal:  Int Orthop       Date:  2017-01-14       Impact factor: 3.075

4.  Instability after total hip arthroplasty.

Authors:  Brian C Werner; Thomas E Brown
Journal:  World J Orthop       Date:  2012-08-18

5.  Method of fixation does not influence the overall risk of rerevision in first-time cup revisions.

Authors:  Maziar Mohaddes; Göran Garellick; Johan Kärrholm
Journal:  Clin Orthop Relat Res       Date:  2013-12       Impact factor: 4.176

6.  Otto Aufranc Award: Dual-mobility Constructs in Revision THA Reduced Dislocation, Rerevision, and Reoperation Compared With Large Femoral Heads.

Authors:  Molly A Hartzler; Matthew P Abdel; Peter K Sculco; Michael J Taunton; Mark W Pagnano; Arlen D Hanssen
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

7.  Can Dislocation of a Constrained Liner Be Salvaged With Dual-mobility Constructs in Revision THA?

Authors:  Brian P Chalmers; Graham D Pallante; Michael J Taunton; Rafael J Sierra; Robert T Trousdale
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

8.  Re-dislocation after revision total hip arthroplasty for recurrent dislocation: a multicentre study.

Authors:  Kensei Yoshimoto; Yasuharu Nakashima; Shigeo Aota; Ayumi Kaneuji; Kiyokazu Fukui; Kazuo Hirakawa; Nariaki Nakura; Koichi Kinoshita; Masatoshi Naito; Yukihide Iwamoto
Journal:  Int Orthop       Date:  2016-02-19       Impact factor: 3.075

9.  Acetabular liner with focal constraint to prevent dislocation after THA.

Authors:  Jacob T Munro; Mihai H Vioreanu; Bassam A Masri; Clive P Duncan
Journal:  Clin Orthop Relat Res       Date:  2013-12       Impact factor: 4.176

10.  Modular tapered implants for severe femoral bone loss in THA: reliable osseointegration but frequent complications.

Authors:  Nicholas M Brown; Matthew Tetreault; Cara A Cipriano; Craig J Della Valle; Wayne Paprosky; Scott Sporer
Journal:  Clin Orthop Relat Res       Date:  2015-02       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.